Lloyd Advisory Services LLC. Buys Shares of 4,665 Bristol-Myers Squibb (NYSE:BMY)

Lloyd Advisory Services LLC. bought a new stake in Bristol-Myers Squibb (NYSE:BMY) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund bought 4,665 shares of the biopharmaceutical company’s stock, valued at approximately $241,000.

Several other institutional investors also recently bought and sold shares of the company. GSA Capital Partners LLP grew its position in shares of Bristol-Myers Squibb by 4.1% during the fourth quarter. GSA Capital Partners LLP now owns 66,286 shares of the biopharmaceutical company’s stock worth $3,401,000 after buying an additional 2,600 shares in the last quarter. Optimist Retirement Group LLC acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth about $410,000. Oarsman Capital Inc. grew its position in shares of Bristol-Myers Squibb by 2.0% during the fourth quarter. Oarsman Capital Inc. now owns 28,021 shares of the biopharmaceutical company’s stock worth $1,438,000 after buying an additional 554 shares in the last quarter. FIL Ltd grew its position in shares of Bristol-Myers Squibb by 1.4% during the fourth quarter. FIL Ltd now owns 7,681,165 shares of the biopharmaceutical company’s stock worth $394,121,000 after buying an additional 107,009 shares in the last quarter. Finally, Voisard Asset Management Group Inc. purchased a new position in Bristol-Myers Squibb in the fourth quarter valued at approximately $73,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. BMO Capital Markets reiterated a “market perform” rating and issued a $48.00 price target on shares of Bristol-Myers Squibb in a research note on Monday, September 23rd. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a research note on Tuesday, July 23rd. TD Cowen increased their price target on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a research note on Monday, October 7th. UBS Group increased their price target on shares of Bristol-Myers Squibb from $50.00 to $54.00 and gave the company a “neutral” rating in a research note on Wednesday. Finally, StockNews.com raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Monday, July 29th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $53.00.

Bristol-Myers Squibb Price Performance

Shares of NYSE BMY opened at $52.19 on Friday. The company has a debt-to-equity ratio of 2.86, a current ratio of 1.16 and a quick ratio of 1.02. The stock has a fifty day moving average price of $49.75 and a 200 day moving average price of $46.43. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $57.65. The company has a market cap of $105.79 billion, a PE ratio of -16.84, a P/E/G ratio of 13.75 and a beta of 0.46.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.64 by $0.43. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The company had revenue of $12.20 billion during the quarter, compared to the consensus estimate of $11.54 billion. During the same quarter last year, the company earned $1.75 earnings per share. Bristol-Myers Squibb’s quarterly revenue was up 8.7% compared to the same quarter last year. Sell-side analysts forecast that Bristol-Myers Squibb will post 0.77 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 1st. Shareholders of record on Friday, October 4th will be issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 4.60%. The ex-dividend date of this dividend is Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.